Opinion|Videos|July 30, 2024
Examining Key Data from DAREON-8
Experts delve into the DAREON-8 Phase 1 clinical trial, assessing the potential impact of incorporating the study into the current treatment algorithm for small cell lung cancer (SCLC).
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- DAREON-8: Phase 1 Clinical Trial of Combination Therapy with BI 764532, a DLL3 Targeting T-Cell Engager
- Please share your opinions of the therapeutic potential of Bl 764532, an lgG-like T-cell engager, for its ability to induce selective T-cell mediated tumor cell lysis when added to SOC (carboplatin + etoposide + atezolizumab) for previously untreated patients with ES-SCLC:
- Is a commercial molecular assay currently available to identify the presence of the delta-like ligand 3 notch receptor in patients with SCLC?
- Are you encouraged by an overall response rate of 28% and a 54% disease control rate in the Phase I trial?
- For which line of therapy do you envision BI 764532, if approved?
- Based on the exclusion criteria for the dose escalation trial, are you concerned that this agent may be associated with cardiovascular, cerebrovascular, and/or immunosuppressive TRAEs?
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
The c-Met–directed ADC was designated for EGFR wild-type nonsquamous NSCLC after platinum chemotherapy and anti–PD-(L)1 therapy.
Firmonertinib did not significantly improve BICR-assessed PFS vs platinum/pemetrexed chemotherapy in first-line EGFR exon 20–mutant NSCLC in FURVENT trial.
Lung cancer experts discuss emerging strategies after immunotherapy in advanced squamous NSCLC, including updated PRESERVE-003 data from WCLC 2026.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
VIR-5500 Receives FDA Fast Track Designation in mCRPC
3
FDA Grants Breakthrough Device Designation to Natera’s Multi-Cancer Early Detection Assay
4
Iberdomide Plus Daratumumab/Dexamethasone Yields Significant PFS Benefit in R/R Myeloma
5